Identification of Risk Factors Parkinson's Disease by Convergence Strategy

NCT03536104 | Completed

• 2 other identifiers: 2008_08112008-A00219-46
• Study Type: observational
• Target: 2,220
• Locations: 1 country
• Sites: 1

Brief Summary

Using this convergence approach from a limited group of subjects with non-diseased controls, patients with Parkinson's disease or related diseases, we will be able to limit the number of potential genes of specific susceptibility to Parkinson disease. These genes will then be studied using a case-control genetic epidemiology approach. The risk of developing the disease will then be evaluated according to clinical, biological and environmental variables collected in Parkinson's subjects and healthy controls in the second group of subjects. The specificity of the genetic associations found will be evaluated in subjects with Parkinson's disease.

Conditions

Parkinson Disease

Outcome Measures

Primary Outcomes (1)

• Significant variations in the frequencies of gene polymorphisms and the risk of developing Parkinson's disease

  the frequency is measured according to biological and environmental variables modulating the risk of developing Parkinson's disease.

  through study completion, an average of 10 years

Study Arms (3)

Controls

This group will include "healthy" person.

Parkinson's patient

This group will include Parkinsonian patients

patients with a related disease.

This group will include patients with a related disease.

Eligibility Criteria

• Age: 18 Years+
• Sex: all
• Healthy Volunteers: Yes
• Age Groups: Adult (18-64), Older Adult (65+)
• Sampling Method: Probability Sample

Study Population

Patients with Parkinson Disease compared to subjects at risk to develop Parkinson Disease and healthy controls

You may qualify if:

• Parkinsonian patients meeting the Gelb criteria
• Patients with other neurodegenerative disease (such as other Parkinson syndrome or synucleopathies) meeting the criteria set out in Appendix 2 (Lewy Bodies dementia, Parkinson's disease with dementia, MultiSystem atrophy, Progressive Supranuclear Paralysis) , Amyotrophic Lateral Sclerosis, Restless Legs Syndrome, Alzheimer's Disease).
• Woman of childbearing age having an effective means of contraception.
• Informed consent signed by the subject or his legal representative.
• For demented subjects coming for consultation or day hospitalization with an accompanying person, signature of the legal representative.
• Absence of rest trembling, bradykinesia and stiffness
• MMSE (Mini Mental State Examination) greater than 25
• Woman of childbearing age having an effective means of contraception.
• subject having signed the informed consent.
• No family history of neurodegenerative disease that started before age 70. These controls will not present any Parkinsonian signs during the clinical evaluation. They may have functional disabilities whose cause is known and unrelated to a neurodegenerative disease with a cognitive function measurement greater than 25 in the MMSE test.

You may not qualify if:

• Functional discomfort in daily life of unknown cause
• MMSE less than 25

Sponsors & Collaborators

• University Hospital, Lille: lead

Study Sites (1)

Hôpital Roger Salengro, CHRU de Lille

Lille, France

Location

Biospecimen

Retention: SAMPLES WITH DNA

serum, plasma, CSF

MeSH Terms

Conditions

Parkinson Disease

Condition Hierarchy (Ancestors)

Parkinsonian Disorders; Basal Ganglia Diseases; Brain Diseases; Central Nervous System Diseases; Nervous System Diseases; Movement Disorders; Synucleinopathies; Neurodegenerative Diseases

Study Officials

• Alain DESTEE, MD, PhD

  University Hospital, Lille

  PRINCIPAL INVESTIGATOR

Study Design

• Study Type: observational
• Observational Model: CASE CONTROL
• Time Perspective: PROSPECTIVE
• Sponsor Type: OTHER
• Responsible Party: SPONSOR

Study Record Dates

• First Submitted: May 14, 2018
• First Posted: May 24, 2018
• Study Start: March 25, 2009
• Primary Completion: November 19, 2024
• Study Completion: November 19, 2024
• Last Updated: December 3, 2025

Record last verified: 2025-12

Data Sharing

• IPD Sharing: Will not share

Locations

FR (1)